The ROE as of December 2024 (TTM) for Exicure, Inc. (XCUR) is -190.90%

According to Exicure, Inc.’s latest financial reports and current stock price. The company's current ROE is -190.90%. This represents a change of 292.73% compared to the average of -48.61% of the last 4 quarters.

Exicure, Inc. (XCUR) Historical ROE (quarterly & annually)

How has XCUR ROE performed in the past?

The mean historical ROE of Exicure, Inc. over the last ten years is -238.33%. The current -190.90% ROE has changed -19.90% with respect to the historical average. Over the past ten years (40 quarters), XCUR's ROE was at its highest in in the September 2022 quarter at 139.35%. The ROE was at its lowest in in the June 2022 quarter at -642.30%.

Exicure, Inc. (XCUR) ROE by Quarter and Year

Discovering the peaks and valleys of Exicure, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Exicure, Inc. (XCUR) Average ROE

How has XCUR ROE performed in the past?

The current ROE of Exicure, Inc. (XCUR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Exicure, Inc. (XCUR) ROE vs. Peers

How is XCUR’s ROE compared to its peers?

Exicure, Inc.’s ROE is greater than Ikena Oncology, Inc. (-39.59%), greater than Enochian Biosciences, Inc. (-73.71%), less than Eliem Therapeutics, Inc. (0%), greater than HCW Biologics Inc. (-2516.87%), less than ZIVO Bioscience, Inc. (618.61%), greater than RenovoRx, Inc. (-242.57%), greater than Tempest Therapeutics, Inc. (-187.44%), greater than Catalyst Biosciences, Inc. (-63.14%), greater than scPharmaceuticals Inc. (-314.97%), greater than Milestone Pharmaceuticals Inc. (-151.81%), greater than Oncolytics Biotech Inc. (-141.94%), less than Seres Therapeutics, Inc. (60.75%), greater than aTyr Pharma, Inc. (-56.83%), greater than Lumos Pharma, Inc. (-233.03%), greater than Marker Therapeutics, Inc. (-89.63%), greater than Protagenic Therapeutics, Inc. (-308.96%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Imunon, Inc. (-57481.16%), less than Cyclacel Pharmaceuticals, Inc. (2.92%), greater than Histogen Inc. (-80.69%), greater than DiaMedica Therapeutics Inc. (-43.68%),

Build a custom stock screener for Exicure, Inc. (XCUR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exicure, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exicure, Inc. (XCUR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exicure, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.